Integra Lifesciences Holdings (IART) Total Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has disclosed Total Current Liabilities across 18 years of filings, most recently posting $330.9 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 64.41% year-over-year to $330.9 million; the TTM figure through Jun 2026 stood at $330.9 million (down 64.41% YoY), while the FY2025 annual figure was $456.0 million, down 50.55% from the prior year.
• Total Current Liabilities came in at $330.9 million for Q2 2026 at Integra Lifesciences Holdings, down from $346.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $929.8 million in Q2 2025 to a low of $282.3 million in Q1 2023.
• Average Total Current Liabilities over 5 years is $465.0 million, with a median of $338.9 million recorded in 2026.
• Year-over-year, Total Current Liabilities jumped 203.73% in 2025 and plunged 64.41% in 2026.
• Over 5 years, Total Current Liabilities stood at $320.9 million in 2022, then slipped by 4.34% to $307.0 million in 2023, then soared by 200.39% to $922.1 million in 2024, then tumbled by 50.55% to $456.0 million in 2025, then declined by 27.44% to $330.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $330.9 million in Q2 2026, $346.8 million in Q1 2026, and $456.0 million in Q4 2025.